Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
2.
Pharmacol Rep ; 73(3): 962-965, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1091991

ABSTRACT

BACKGROUND: Amantadine is a drug that can help in the prevention of SARS-CoV-2 symptomatology, as has been demonstrated in observational clinical studies. METHODS: We searched in the PubMed database Clinical Studies of coronavirus-infected patients who have been treated with amantadine in a preventive manner as well as patients with Parkinson's disease. RESULTS: Four clinical studies were found in which relatives of patients with COVID-19 had been prescribed the use of amantadine in a preventive manner to avoid the symptoms caused by the coronavirus. CONCLUSION: Amantadine is a drug that can be prescribed as a prophylactic that prevents symptomatology caused by SARS-CoV-2 coronavirus.


Subject(s)
Amantadine/therapeutic use , Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , SARS-CoV-2/drug effects , Humans
3.
Arch Med Res ; 51(7): 739-740, 2020 10.
Article in English | MEDLINE | ID: covidwho-1023466

ABSTRACT

SARS-Cov-2, whose symptoms include difficulty swallowing, coughing, diarrhea, and breathing failure, has caused the loss of many lives around the world. In the absence of a vaccine or medication to help prevent or decrease the effects of the disease, we suggest that amantadine may reduce the effects of COVID-19.


Subject(s)
Amantadine/therapeutic use , Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , Humans , SARS-CoV-2
4.
Pharmacol Rep ; 72(6): 1538-1541, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-842967

ABSTRACT

BACKGROUND: We conducted an observational study of 15 patients from a Southeastern area of Mexico with symptoms compatible with SARS-Cov-2, which were treated with the antiviral amantadine. METHODOLOGY: In this study, data were collected from 15 individuals with clinical symptoms of COVID-19 infection, which were treated on an ambulatory basis with 100 mg of amantadine for a period of 14 days. RESULTS: This drug demonstrated its effectiveness, as patients recovered successfully with this treatment without the necessity of attending a hospital to use mechanical ventilation. All patients developed IgG antibodies to SARS-Cov-2. CONCLUSION: Amantadine can be used as a viable and cost-effective alternative for treating people with severe acute respiratory syndrome (SARS-Cov-2) on an ambulatory basis, while the vaccine is not available.


Subject(s)
Amantadine/therapeutic use , Ambulatory Care , Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Mexico , Middle Aged , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL